MedTrace Logo

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

NCT02002208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2018-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).

Conditions

Interventions

DRUG

OC000459

Oral CRTH2 antagonist

Sponsors & Collaborators

  • Atopix Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Michael Cork, MB · University of Sheffield

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-09-30
Completion
2016-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02002208 on ClinicalTrials.gov